Prognosis
AstraZeneca’s Diabetes Drug Farxiga Lowers Death Risk in Heart Failure
- Results open door to wider use of Astra’s diabetes treatment
- New treatments needed for condition that affects 64 million
Photographer: Chris Ratcliffe/Bloomberg
This article is for subscribers only.
AstraZeneca Plc’s Farxiga helped stave off death in a study of patients with heart failure, opening the door to a new use for the diabetes treatment.
Adding the drug to standard therapy reduced the risk of death or worsening heart failure in patients with and without diabetes, according to a statement Tuesday. The shares rose as much as 1.9% in London.